HUM — Humana Inc.

Price action is unambiguously bullish: as of 2026-09-13 HUM was +147.72% over six months, +8.06% over three months, +5.39% over one month, and +44.69% above its 200-day SMA, with RSI(14) at 63.33 — strong but not yet overbought. The fuel was Q2 2026 (reported 2026-07-29): adjusted EPS of $7.61 versus ~$6.81 consensus on ~26% revenue growth, with the insurance benefit ratio at 91.2% and operating cost ratio up 120bps YoY. Notably, management only *affirmed* FY2026 guidance (adjusted EPS 'at least $9.00', benefit ratio target 92.75% ±25bps) rather than raising it, which triggered a brief late-July pullback — that failure to raise is the single biggest tell that the Street's enthusiasm is running ahead of reported results. Sell-side positioning is far cooler than the tape: consensus rating is Hold (26 hold, 17 buy, 1 sell, 0 strong buy) with a $418.53 average price target — only ~2% above the 2026-09-13 price. So the honest read is bullish *price*, neutral *fundamentals*, and a stock that has already banked most of the visible good news.

Revenue is genuinely accelerating: quarterly revenue stepped from $26.4B (Q3 2023) to $29.2–29.6B through 2024, to $32.1–32.6B through 2025, then jumped to $39.65B in Q1 2026 (+23.5% YoY) and $40.87B in Q2 2026 (+26.2% YoY). That 2026 step-up is far larger than Medicare Advantage membership growth can explain, so a meaningful chunk is mix/acquisition (CenterWell, MaxHealth) rather than pure organic pricing — treat the '26% growth' headline with that caveat. Earnings, by contrast, are not yet inflecting: GAAP EPS has been deeply seasonal and volatile for three straight years with Q4 losses every year (-$4.42 in Q4 2023, -$5.76 in Q4 2024, -$6.61 in Q4 2025) and Q1 as the profit quarter ($10.30 in Q1 2025, $9.83 in Q1 2026). Margins are the real story and they are still compressing, not expanding: gross margin fell from ~17.7% (Q3 2023) to ~13.4% (Q2 2026), and operating margin in Q1 2026 (4.0%) was below Q1 2025 (5.1%). Free cash flow is lumpy and poor — TTM FCF is roughly -$443M (Q2 2026 alone was -$558M, Q4 2025 -$1.85B), offset by Q1 2026's +$1.13B. Verdict: revenue is accelerating, profitability is still searching for a bottom. The Q2 2026 EPS beat was a cost-control 'less bad' quarter, not a margin inflection — confirmed by the fact guidance was merely reaffirmed. The genuine inflection candidate is 2028, when 2027 Star Ratings feed into bonus revenue.

Expensive on anything you can measure today. As of 2026-09-13 the stock traded at 38.5x TTM EPS of $10.632 versus a 5-year average P/E of 23.5x; on the ~$9.15 next-FY consensus EPS the forward multiple is ~44.8x, and PEG is negative (-2.078) because earnings are falling, so there is no growth-adjusted framing that makes the multiple look cheap. P/B is 2.56x, and P/S of 0.338 looks 'cheap' versus the 5-year average of 0.49 only because the revenue denominator inflated in 2026 — not a real signal. Supporting the valuation: net margin 0.9%, operating margin 1.4%, ROIC 3.1%, ROE 6.7%, and negative TTM FCF. What you are actually paying for is normalization, not current earnings: to justify $409.85 at a 16x multiple you need roughly $25.50 of EPS — i.e., net income of ~$3.0B versus ~$1.1B implied by FY2026 adjusted guidance. That is a return to 2021–2023 profitability levels, which is plausible but far from proven and is the entire bull case.

The stock is pricing in a recovery that has not yet shown up in reported numbers. TTM EPS is $10.63, FY2026 guidance is 'at least $9.00' adjusted (and only ~$6.52 GAAP, implying roughly a -$9 GAAP loss across H2 2026 given Q1+Q2 already booked +$15.55), and consensus for the next fiscal year sits at $9.154 — essentially flat. So at $409.85 you are paying ~45x near-term earnings for flattish EPS. The only way that math works is if EPS roughly doubles to $20–25 by 2028–2029 via the 150bps cost-ratio program plus 2028 Star Ratings bonus recovery. Practical playbook: watch the direction of revisions, not the multiple. If FY2027/FY2028 EPS estimates don't start migrating higher after the October 2026 Star Ratings and the December 10 2026 investor update, the multiple compresses and there is no earnings growth to catch the fall. A positive Stars print, by contrast, would validate today's price immediately. The asymmetry has shifted: a beat in Q2 bought zero upward guidance revision, which historically warns that expectations are ahead of delivery.

As of 2026-09-13, RSI(14) stood at 63.33 — firm, not overbought. Price was +4.55% above the 20-day SMA (~$392), +5.34% above the 50-day SMA (~$389), and a striking +44.69% above the 200-day SMA (~$283), reflecting the 147.72% six-month melt-up from the $163.11 low. This is a clean, strong uptrend near the $428.88 52-week high, but the 200-day extension is about as stretched as it gets — the stock would have to fall roughly 31% just to touch its long-term mean. Entry-timing implication: this is not a chase level. Short-term trend support sits at the 20/50-day cluster around $389–392; a break of that, or a disappointing October Stars print, is the most likely trigger for a sharp mean-reversion move. Scale in rather than buy in full, and keep dry powder for the Q3 print (2026-11-04) and the December investor day.

• Medicare Advantage reimbursement: CMS benchmark rate updates plus the V28 risk-adjustment phase-in directly reset Humana's revenue per member — the single largest structural swing factor for a company with the vast majority of revenue in government programs.
• Star Ratings / quality bonus payments: Humana is still absorbing the impact of prior-year Star downgrades on bonus revenue; the 2027 ratings (published October 2026) set 2028 bonus dollars, making this a binary regulatory driver rather than a gradual trend.
• Elevated senior medical utilization: sector-wide post-pandemic utilization remains high, and Humana's 92.75% ±25bps benefit-ratio target for FY2026 leaves little cushion if acuity re-accelerates.
• Rates and capital costs: with ~$12.0B of long-term debt and a 0.742 debt/equity ratio, the 10-year yield influences both interest expense and the discount rate applied to long-duration insurance earnings; low beta (0.745) also makes HUM a defensive rotation beneficiary in risk-off tape.
• IRA Part D redesign and Medicaid state contracting: shifting drug-cost liability plus new state awards (e.g., Humana selected as sole new entrant for statewide Illinois Medicaid managed care launching January 2027) are reshaping the growth mix away from pure MA.

• CMS 2027 Star Ratings release in October 2026 — binary for 2028 quality-bonus revenue and the credibility of the entire multi-year recovery thesis; management has explicitly declined to preview it.
• Q3 2026 earnings on 2026-11-04 — consensus models a -$0.95 EPS seasonal loss; the real test is whether the benefit ratio tracks toward the 92.75% full-year target and whether the 120bps cost-ratio improvement holds.
• Virtual Investor Update on 2026-12-10 — management to lay out 2028 Star-recovery trajectory and preliminary 2027 membership expectations, the first real forward-looking numbers since guidance was set.
• Gentiva minority-stake divestiture (~$900M, closing Q4 2026) plus MaxHealth clinic integration and the $1.5B contingent capital (PCAPs) facility — capital allocation that funds the CenterWell build-out.
• Illinois statewide Medicaid managed care contract launch in January 2027 — a tangible, non-MA growth leg to offset Medicare Advantage rate pressure.

• Star Ratings disappointment in October 2026 would delay the 2028 earnings recovery that a ~45x forward multiple already assumes — the highest-impact single risk in the next 90 days.
• Benefit-ratio / medical-cost re-acceleration: a Q2 2026 adjusted-EPS beat produced zero upward guidance revision, which implies Humana still sees full-year risk; the 92.75% benefit-ratio target has limited slack.
• Earnings quality and cash generation: TTM free cash flow is roughly -$443M, Q2 2026 FCF was -$558M, and the accruals ratio of 1.96% (positive, meaning net income is running slightly ahead of operating cash flow) is a mild caution flag in a business with violent seasonal cash swings.
• Regulatory/reimbursement: further MA rate cuts, V28 coding phase-in, and IRA Part D cost-shifting could permanently reset the margin ceiling below Humana's 2021–2022 baseline (operating margin ~4.2%).
• Valuation and momentum risk: +147.72% in six months, +44.69% above the 200-day SMA, 38.5x TTM vs. a 23.5x 5-year average — the stock is priced for success, and a miss would unwind the momentum premium quickly.
• Concentration: heavy dependence on Medicare Advantage versus more diversified peers leaves Humana disproportionately exposed to a single policy regime.

Humana is a real turnaround story, not a broken business: Q2 2026 adjusted EPS of $7.61 beat the ~$6.81 consensus, revenue grew ~26% YoY, the operating cost ratio improved 120bps with a 150bps full-year target, the balance sheet is sound (0.742 debt/equity, 1.742 current ratio, $6.9B cash), and management is taking real action (Gentiva divestiture, MaxHealth, new CMO, Illinois Medicaid win). But at $409.85 as of 2026-09-13 you are paying 38.5x trailing and ~45x next-year earnings for a company whose FY2026 adjusted EPS guidance is only 'at least $9.00' and whose TTM free cash flow is negative — and the stock has already tripled off $163.11 in six months. The recovery is priced in ahead of the October 2026 Star Ratings binary, which is the one event that actually determines whether 2028 earnings support today's multiple. This is a fairly-valued, catalyst-dependent hold, not a fresh buy at these levels: I would want either the Stars print behind me or a pullback toward the $389–392 20/50-day cluster before adding. This is analysis, not personalized financial advice.

Normalized-earnings × justified-P/E. I use a mid-cycle net income of ~$3.0B — the 2021–2023 average, i.e., roughly what a ~1.85% net margin on FY2026E revenue of ~$162.5B produces once the 150bps cost-ratio program and 2028 Star bonus recovery land — divided by ~120.2M diluted shares to get ~$25.00 of normalized EPS. I then apply 15.5x, a discount to Humana's 23.5x 5-year average (inflated because the average spans trough-earnings years) and in the middle of the 13–18x range Medicare Advantage plans have historically commanded through a cycle. 15.5 × $25.00 = $387.50, rounded to $388 — about 5% below the 2026-09-13 price of $409.85 and below the $418.53 analyst consensus target, implying the market has already paid for a recovery that has yet to appear in reported GAAP earnings or free cash flow.